Products Categories

  • Mr.Bruce Li
    Tel: +86-027-83214688

  • Ms.Linda Yang
    sales
    Tel: +8618874586545

  • Ms.Niyoe Tan
    sales
    Tel: 17720330692

  • Ms.rany
    Tel: +8618627068784

  • Ms.Yuki
    Tel: +8618871152735

  • Mobile:
  • Tel:+86-027-83214688
  • Fax:02783214688
  • Province/state:Hubei
  • City:Wuhan
  • Street:666 Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan City, Hubei Province, China
  • MaxCard:
Home > Products >  99% Fulvestrant 129453-61-8 Treatment Of Breast Cancer

99% Fulvestrant 129453-61-8 Treatment Of Breast Cancer CAS NO.129453-61-8

  • Min.Order: 10 Gram
  • Payment Terms: T/T,
  • Product Details

Keywords

  • 99% Fulvestrant
  • Fulvestrant Manufacturer
  • Treatment Of Breast Cancer

Quick Details

  • ProName: 99% Fulvestrant 129453-61-8 Treatment ...
  • CasNo: 129453-61-8
  • Molecular Formula: C32H47F5O3S
  • Appearance: White Powder
  • Application: It Can Be Used As Pharmaceutical Inte...
  • DeliveryTime: 2-4 days after confirming your payment...
  • PackAge: 100g/ bag, 2 kg/ bag, 25kg/ carton or ...
  • Port: Wuhan
  • ProductionCapacity: 10000 Metric Ton/Month
  • Purity: 99%
  • Storage: Store in sealed containers at cool & d...
  • Transportation: By DHL, TNT, FedEx, HKEMS, UPS, Etc
  • LimitNum: 10 Gram

Superiority

 

Advantages:
 
Hubei XinRunde Chemical Co., Ltd is a renowned pharmaceutical manufacturer. We can offer high quality products at competitive price in quick delivery with 100% custom pass guaranteed. Never stop striving to offer our best service is our philosophy. We have Flexible and Untraceable payment terms. As a leading manufacture, our products have been exported to Germany, Norway, Poland, Finland, Spain, UK, France, Russia, USA, Brazil, Mexico, Australia, Japan, Korea, Thailand, Indonesia, Uruguay and many other countries.

 

1. Quality.Every batch of steroid powders have tobetested by our QC(quality control) before they are allowed to sell.


2. Delivery We have stock, so we can delivery quickly at the very day when receive the payment. Within 24 hours after receiving the payment Lead time 4 or 7 days.


3. Discreet package Safelyand Professionally Disguised Package Guaranteed. For your safety and to insure delivery all products will be packed in a discreet way to prevent any suspicions, no steroids related name will appear on the parcels. high successful delivery rate.


4. Warm after-sale service Any of your question would be solved for the first as soon as possible.

 

Details

Fulvestrant Basic information
Indications and Usage Mechanisms of Action Pharmacokinetics Adverse reactions
Product Name: Fulvestrant
Synonyms: (7a,17b)-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol;7A,17B-[9[(4,4,5,5,5-PENTAFLUOROPENTYL)SULFINYL]NONYL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL;(7alpha,17beta)-nonyl);estra-1,3,5(10)-triene-3,17-diol,7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl);zd182780;zm182780;(717b)- 7-[9-[4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol;ICH-182780
CAS: 129453-61-8
MF: C32H47F5O3S
MW: 606.77
EINECS: 1308068-626-2
Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Nuclear Receptors;Chiral Reagents;Steroids;Sulfur & Selenium Compounds;FASLODEX;Anti-cancer&immunity;Inhibitors
Mol File: 129453-61-8.mol
Fulvestrant Structure
 
Fulvestrant Chemical Properties
Melting point  104-106°C
storage temp.  2-8°C
solubility  DMSO: >5mg/mL
InChIKey VWUXBMIQPBEWFH-WCCTWKNTSA-N
CAS DataBase Reference 129453-61-8(CAS DataBase Reference)
 
Safety Information
RTECS  KG7623000
Hazardous Substances Data 129453-61-8(Hazardous Substances Data)
 
Fulvestrant Usage And Synthesis
Indications and Usage Fulvestrant is a muscle injection drug developed by the company AstraZeneca and is suitable for treating postmenopausal women with estrogen receptor-positive metastasized breast cancer whose condition continued to worsen despite antiestrogen treatment. Fulvestrant is the only antiestrogen drug that can be widely clinically used following unsuccessful tamoxifen treatment. This drug is a type of endocrine therapy, so it will not cause any adverse effects commonly seen in chemotherapy, giving it relatively good patient compliance. Multiple clinical trials have found that 250mg Fulvestrant is effective and consistently safe as a second line of treatment for advanced breast cancer.
Mechanisms of Action Many breast cancer cells contain estrogen receptors (ER), so estrogen stimulates breast cancer growth. Fulvestrant is a steroid estrogen receptor antagonist, and its chemical structure is similar to estradiol, except that its 7α position contains a linking group. Fulvestrant is a 17β-estradiol alkylamine analogue, and it binds with, prevents, and decreases ER to inhibit the estrogen signal transduction pathway. It binds competitively with ER, has a similar affinity with ER as estrogen, and inhibits gene activation stimulated by estrogen, thus affecting necessary estrogen-related processes in cell circulation. Its fulvastans have a similar affinity with ER as estrogen and is 100 times that of tamoxifen.
Pharmacokinetics Fulvestrant has a relatively poor oral bioavailability, so it is commonly injected into the muscle with lipids as excipients. In an open, random and multicenter study on postmenopausal women with advanced breast cancer, one 5ml or 2 2.5ml dosages containing 250mg were injected, and their pharmacokinetics and poisonous side effects did not differ greatly, while its blood concentration was dose-dependent and had individual differences. In the 7-day treatment period, serum LH, FSH or SBHG levels did not change significantly. This drug does not pass through the blood-brain barrier and will not cause side effects such as vasomotor symptoms.
Adverse reactions Fulvestrant causes relatively fewer side effects, including brief vaginal bleeding, body odor change, and sleepwalking. There have not been any reports of effects such as vaginal dryness, weight gain, blood clotting abnormalities, thrombus formation and libido change, and characteristics such as facial flushing and sweating are not affected. A small-scale stage III clinical trial on 19 women with metastasized breast cancer who used this drug showed that its clinical efficacy was 67% and there were no serious safety issues. It showed that continuous monthly injections were crucial and that it was well-tolerated, with only slight swelling and paint at injection site, while facial flushing, uterine lining thickness, sex hormone binding globulin levels, follicle stimulating hormones levels, and luteinizing hormone levels all showed no change.
Chemical Properties White Powder
Uses A novel steroidal estrogen antagonist reported to lack any partial agonist activity. Antineoplastic (hormonal).
Uses antiestrogen
Definition ChEBI: A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.
Biological Activity A high affinity estrogen receptor antagonist (IC 50 = 0.29 nM), devoid of any partial agonism both in vitro and in vivo . Also high affinity agonist at the membrane estrogen receptor GPR30.

 

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog